Marinomed Biotech AG (MARI.VI)
EUR 15.9
(0.32%)
EUR 15.9
(0.32%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.52 Million | -5.2 Million | -4.86 Million | -6.88 Million | -7.64 Million | -4.31 Million |
| Net Income | -6.79 Million | -6.39 Million | -5.89 Million | -6.01 Million | -7.21 Million | -12.09 Million |
| Depreciation & Amortization | 678.2 Thousand | 669.7 Thousand | 608.9 Thousand | 428.4 Thousand | 327.2 Thousand | 236.76 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 732 Thousand | -455 Thousand | -809.8 Thousand | -1.53 Million | -1.72 Million | 1.51 Million |
| Other non-cash items | 856.4 Thousand | 980.1 Thousand | 1.22 Million | 231 Thousand | 976 Thousand | 6.03 Million |
| Investing Cash Flow | -128.5 Thousand | -207.5 Thousand | -918.8 Thousand | -3.96 Million | -2.37 Million | -228.91 Thousand |
| Investments in PPE | -128.5 Thousand | -227.6 Thousand | -918.8 Thousand | -3.96 Million | -2.34 Million | -229.08 Thousand |
| Acquisitions | - | 20.1 Thousand | - | - | - | 170.00 |
| Investment purchases | - | - | - | - | -35 Thousand | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -128.5 Thousand | - | - | - | - | 170.00 |
| Financing Cash Flow | -929.7 Thousand | 7.78 Million | 2.38 Million | 8 Million | 20.32 Million | 229.66 Thousand |
| Debt repayment | -922.4 Thousand | -200 Thousand | -300 Thousand | -210 Thousand | -4.17 Million | -619.3 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 304.1 Thousand | 306 Thousand | 22.42 Million | 867.64 Thousand |
| Other Financing Activities | -7300.00 | 7.98 Million | 2.37 Million | 7.9 Million | 2.07 Million | -18.67 Thousand |
| Accounts receivables | 995.6 Thousand | 1.52 Million | -784.8 Thousand | -2.04 Million | -1.32 Million | -9928.36 |
| Accounts payables | - | -1.52 Million | 784.8 Thousand | 2.04 Million | -870.7 Thousand | 1.65 Million |
| Inventory | 549.7 Thousand | -534.7 Thousand | -101.3 Thousand | -828.6 Thousand | 18.2 Thousand | 62.01 Thousand |
| Other working capital | -813.3 Thousand | 79.7 Thousand | -708.5 Thousand | -705.5 Thousand | 453 Thousand | 1.44 Million |
| Cash at beginning of period | 8.17 Million | 5.8 Million | 9.2 Million | 12.01 Million | 1.71 Million | 6.03 Million |
| Cash at end of period | 2.58 Million | 8.17 Million | 5.8 Million | 9.2 Million | 12.01 Million | 1.71 Million |
| Capital Expenditure | -128.5 Thousand | -227.6 Thousand | -918.8 Thousand | -3.96 Million | -2.34 Million | -229.08 Thousand |
| Effect of forex changes on cash | 11 Thousand | 100.00 | 100.00 | 30.2 Thousand | - | 0.97 |
| Net cash flow / Change in cash | -5.58 Million | 2.37 Million | -3.4 Million | -2.81 Million | 10.3 Million | -4.31 Million |
| Free Cash Flow | -4.65 Million | -5.43 Million | -5.78 Million | -10.84 Million | -9.98 Million | -4.54 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | -1.19 Million | -6.79 Million | -2.09 Million | -1.45 Million | -2.05 Million |
| Depreciation & Amortization | - | 165.9 Thousand | 678.2 Thousand | 169.1 Thousand | 176 Thousand | 167.3 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | 732 Thousand | - | - | - |
| Other non-cash items | -944.7 Thousand | 640.3 Thousand | 856.4 Thousand | 54.89 Thousand | -243.6 Thousand | 1.13 Million |
| Investing Cash Flow | - | -4900.00 | -128.5 Thousand | - | -97.2 Thousand | -26.4 Thousand |
| Investments in PPE | - | - | -128.5 Thousand | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 211.6 Thousand | 209.9 Thousand | -929.7 Thousand | -767.7 Thousand | -1100.00 | -370.8 Thousand |
| Debt repayment | - | - | -922.4 Thousand | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 211.6 Thousand | - | - | - | - | - |
| Accounts receivables | - | - | 995.6 Thousand | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | 549.7 Thousand | - | - | - |
| Other working capital | - | - | -813.3 Thousand | - | - | - |
| Cash at beginning of period | 2.58 Million | 2.76 Million | 8.17 Million | 5.4 Million | 7.02 Million | 8.17 Million |
| Cash at end of period | 1.85 Million | 2.58 Million | 2.58 Million | 2.76 Million | 5.4 Million | 7.02 Million |
| Capital Expenditure | - | - | -128.5 Thousand | - | - | - |
| Effect of forex changes on cash | - | -200.00 | 11 Thousand | - | -100.00 | - |
| Net cash flow / Change in cash | -733.1 Thousand | -180.1 Thousand | -5.58 Million | -2.63 Million | -1.61 Million | -1.15 Million |
| Free Cash Flow | -944.7 Thousand | -384.9 Thousand | -4.65 Million | -1.86 Million | -1.51 Million | -755.8 Thousand |
8367
BLKASHYAP
8091
4441
ORINF
USREF